We have very good news for dog owners! We have completed the 168th day of patient follow-up after a single administration of BCX-CM-AD for atopic dermatitis. The conclusions?<\/p>\n
In nearly half of the patients who received BCX-CM-AD, the therapeutic effect is maintained for at least 6 months. This means that a single dose of our drug candidate may provide efficacy in reducing skin lesions and pruritus comparable to at least 6 months of monoclonal antibody treatment.<\/p>\n
Based on the obtained results, we can conclude that in the study group compared to baseline:<\/p>\n
\u2714\ufe0f skin lesions (according to CADESI-4) were reduced on average by approximately 82%
\n\u2714\ufe0f pruritus levels (according to PVAS) were reduced on average by approximately 62%<\/p>\n
Importantly, the levels of symptom reduction are at their highest at the end of the study. This allows us to formulate a reasonable hypothesis that the therapeutic effect may last even longer.<\/p>\n
Not only the dogs are satisfied. Nearly 80% of veterinarians and over 80% of owners rated the treatment response as good or excellent.<\/p>\n
BCX-CM-AD may define a new standard of care for atopic dermatitis in companion animals. The additional results significantly strengthen the position of our product. This is an important step toward bringing Bioceltix\u2019s innovative therapy to the market.<\/p>\n